Scilex Holding Company Announces Update Regarding Distribution of Dream Bowl 2026 Meme Coin by Datavault AI Inc.

Rhea-AI Summary

Scilex Holding Company (Nasdaq: SCLX) said Datavault AI (Nasdaq: DVLT) intends to voluntarily distribute Dream Bowl 2026 Meme Coins to Scilex record holders as of November 25, 2025, concurrent with Datavault AI's own eligible holders.

Nasdaq told Datavault AI it will not make an announcement for Scilex about the distribution date. Distribution is conditional on recipients opting in, setting up a Data Vault® wallet, and providing documentation. Datavault AI's board may change the record date and will set the payment date within 60 days after the record date; payment is conditioned on the board not revoking the distribution.

Insights

Corporate Actions Analyst

Datavault AI plans a voluntary airdrop of "Dream Bowl 2026" meme coins to Scilex record holders; distribution is optional and conditional.

Datavault AI intends to airdrop Dream Bowl 2026 meme coins to holders of Scilex common stock of record as of November 25, 2025, subject to recipients opting in and establishing a Data Vault® wallet. Nasdaq will not announce a record or ex-dividend date for Scilex, and Datavault AI’s Board may change the record date or revoke the distribution; payment timing will be set within 60 days after the record date and follows the Board’s solvency/surplus analysis.

The mechanics create several practical constraints: recipients must complete wallet setup and provide documentation to receive tokens, the distribution depends on corporate-board resolution and solvency review, and lack of a Nasdaq announcement may reduce market clarity about entitlement. Watch for a confirmed payment date within 60 days of the record date, the final Board resolution or any revocation, and the follow-up instructions on opt-in and wallet setup ahead of the payment date; expect these items to resolve in the near term around the announced record date and the subsequent 60-day window.

PALO ALTO, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, announced today that, with respect to the voluntary distribution by Datavault AI Inc. (“Datavault AI”) (Nasdaq: DVLT) of Dream Bowl 2026 Meme Coins to record holders of Scilex common stock, given that such distribution is being made by Datavault AI as a token of its appreciation for Scilex’s relationship with Datavault AI as a stockholder of Datavault AI, licensing partner and co-sponsor of the Dream Bowl XIV event to be held on January 11, 2026, Nasdaq has informed Datavault AI that it is not planning to make any announcement for Scilex regarding such distribution, whether as to the record date or an ex-dividend date. Notwithstanding the absence of such announcement, Datavault AI has informed the Company that it intends to make such voluntary distribution to record holders of Scilex common stock as of November 25, 2025 concurrently with the distribution of the Dream Bowl 2026 Meme Coins to Datavault AI’s eligible record equity holders, including the Company.

The Dream Bowl 2026 Meme Coins will be airdropped to Data Vault^® wallets following the payment date for the distribution, subject to recipient’s electing to opt-in to the distribution and setting up a digital wallet with Datavault AI and providing Datavault AI with documentation confirming same. Subject to the right of the Board of Directors of Datavault AI to change the record date, the payment date for this distribution will be determined by subsequent resolutions of the Board of Directors of Datavault AI, which will be within 60 days following the record date. Further instructions regarding wallet setup, token access, and distribution procedures will be provided by Datavault AI in a subsequent communication prior to the payment date.

The record date for the distribution may be changed by the Board of Directors of Datavault AI for any reason at any time prior to the actual payment date, and payment of the distribution is conditioned upon the Board not having revoked the dividend prior to the payment date, including for a material change to the solvency or surplus analysis presented to the Board of Directors of Datavault AI. 

For more information on Scilex Holding Company, refer to www.scilexholding.com

For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com

For more information on ZTlido^® including Full Prescribing Information, refer to www.ztlido.com.

For more information on ELYXYB^®, including Full Prescribing Information, refer to www.elyxyb.com.

For more information on Gloperba^®, including Full Prescribing Information, refer to www.gloperba.com.

https://www.facebook.com/scilex.pharm

https://www.linkedin.com/company/scilex-holding-company/

info@scilexholding.com

About Scilex Holding Company

Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido^® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB^®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba^®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.

Scilex is headquartered in Palo Alto, California.

Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, Datavault AI’s potential distribution of the Dream Bowl 2026 Meme Coin and the timing thereof (including that the Board of Directors of Datavault AI may change the record date and, as a result, the payment date thereof), future opportunities for Scilex and its subsidiaries, the future business strategies, long-term objectives and commercialization plans of Scilex and its subsidiaries, the current and prospective product candidates, planned clinical trials and preclinical activities and potential product approvals, as well as the potential for market acceptance of any approved products and the related market opportunity of Scilex and its subsidiaries, statements regarding SP-102, if approved by the FDA, Scilex’s potential to attract new capital and avoid the effects of negative debt leverage and other statements that are not historical facts. These statements are based on management’s current expectations of and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, general economic, political and business conditions; risks related to legal proceedings that may be instituted against the parties regarding the Dream Bowl 2026 Meme Coin and the distribution thereof to holders of Scilex common stock; the risks associated with the right of the Board of Directors of Datavault AI to change the record date (and, as a result, the payment date) of the distribution of, and/or to revoke, the Dream Bowl 2026 Meme Coin; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; the risk of failure to realize the anticipated benefits of the transactions contemplated with Datavault and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.

Contacts:

Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310

Email: investorrelations@scilexholding.com

Website: www.scilexholding.com

SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.

ZTlido^® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.

Gloperba^® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.

ELYXYB^® is a registered trademark owned by Scilex Holding Company.

Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc.

All other trademarks are the property of their respective owners.

© 2025 Scilex Holding Company All Rights Reserved.

FAQ

What is the record date for the Dream Bowl 2026 Meme Coin distribution to SCLX holders?

Datavault AI has indicated a record date of November 25, 2025, subject to change by Datavault AI's board.

Do SCLX shareholders automatically receive Dream Bowl 2026 Meme Coins on the payment date?

No. Recipients must opt in, set up a Data Vault® wallet with Datavault AI, and provide documentation to receive the airdrop.

When will the payment date for the Datavault AI distribution to SCLX holders be set?

The payment date will be determined by subsequent board resolutions of Datavault AI and will be within 60 days after the record date.

Will Nasdaq announce an ex-dividend or record date for SCLX regarding the meme coin distribution?

Nasdaq informed Datavault AI it is not planning to make any announcement for Scilex about the record date or an ex-dividend date.

Can Datavault AI revoke the distribution before the payment date?

Yes. Payment is conditioned on the board not having revoked the distribution prior to the payment date, including for material changes to solvency or surplus analysis.

Where will the Dream Bowl 2026 Meme Coins be delivered for eligible SCLX holders?

The coins will be airdropped to Data Vault® wallets after the payment date, subject to each recipient's opting in and wallet setup.